Meeder Asset Management Inc. Decreases Stock Holdings in Natera, Inc. $NTRA

Meeder Asset Management Inc. lowered its position in shares of Natera, Inc. (NASDAQ:NTRA) by 24.9% in the first quarter, HoldingsChannel.com reports. The firm owned 23,954 shares of the medical research company’s stock after selling 7,961 shares during the quarter. Meeder Asset Management Inc.’s holdings in Natera were worth $4,791,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Horizon Investments LLC lifted its holdings in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares during the last quarter. Sound Income Strategies LLC increased its holdings in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 45 shares during the last quarter. Savvy Advisors Inc. increased its holdings in shares of Natera by 3.1% in the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after acquiring an additional 46 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after acquiring an additional 47 shares in the last quarter. Finally, First Horizon Corp raised its position in shares of Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after acquiring an additional 51 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer owned 108,743 shares of the company’s stock, valued at $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Rowan E. Chapman sold 2,964 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total value of $642,535.92. Following the completion of the transaction, the director owned 3,124 shares in the company, valued at $677,220.72. This trade represents a 48.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,872 shares of company stock worth $39,627,696 over the last 90 days. 5.05% of the stock is owned by corporate insiders.

Natera Stock Performance

NTRA stock opened at $271.39 on Monday. The company has a market capitalization of $38.87 billion, a P/E ratio of -166.50 and a beta of 1.51. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04. The business has a 50 day simple moving average of $233.97 and a 200-day simple moving average of $220.33.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Natera in a research report on Monday, July 6th. Canaccord Genuity Group upped their target price on shares of Natera from $285.00 to $330.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.